Yaroslavl region

Yaroslavl region
in numbers
Foreign investors
in Yaroslavl region
Yaroslavl Region Development Corporation, JSC
Address: 150014, the city of Yaroslavl, Svobody str., 71A
Website: https://invest76.ru
E-mail: corporation@invest76.ru
Tel.: +7 (4852) 230-230
Fax: +7 (4852) 230-230
Time zone: Москва +0

 

News

07.06.2021
Takeda Pharmaceuticals, Japan, one of the world's largest pharmaceutical companies, is going to invest RUB 2.3 billion in expanding the production of medicines at its factory in the Yaroslavl Region. The agreement was signed on Thursday at the St. Petersburg International Economic Forum 2021 by Dmitry Mironov, the Region’s Governor, and Chris Buttkus, Director of Takeda Russia factory in Yaroslavl, the company's press office said.
12.06.2019
KamAZ and Weichai PowerCo (China) will open a joint venture for the production of industrial engines (power from 520 to 2 thousand kW) on the basis of PJSC Tutaev Motor Plant (KamAZ subsidiary) in the Yaroslavl Region by 2020. The volume of announced investments amounted to 760 million rubles, according to the website of the Russian automaker.
01.02.2019
Besins Healthcare pharmaceutical company has been completed in the Industrial Park Novoselki.The company will produce the micronized progesterone, which is a full analogues of a feminine hormone. The drug has been widely used in the sphere of Obstetrics and Gynaecology and is included in the list of vital medicines.
05.09.2020
The joint venture of KAMAZ and Chinese Weichai has launched mass production of diesel and gas engines in Tutaev, a release of the Yaroslavl regional government says.
01.02.2019
Besins Healthcare pharmaceutical plant has been completed in Novoselki Industrial Park, Yaroslavl. The company is to produce micronized progesterone, a female hormone equivalent. The drug has been widely used in obstetrics and gynaecology and is included in the essential medicines list.
04.08.2018
Japanese pharmaceutical company Takeda invested over 98 million euros in the production of pharmaceuticals in Russia, 477 million rubles of which were assigned to the production of innovation orphan drug Ixazomib named Ninlaro for patients with multiple myeloma (blood cancer). This information was provided to TASS by a company’s press service representative at the opening ceremony of the drug manufacturing site of the plant in Yaroslavl.

Select a region